Tumor-induced osteomalacia

Emily G. Farrow, Kenneth E. White

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Tumor-induced osteomalacia (TIO) is an acquired disorder of isolated renal phosphate wasting associated with tumors, typically of mesenchymal origin. Patients with TIO share similar biochemical and skeletal phenotypes with patients who have autosomal dominant hypophosphatemic rickets (ADHR) and X-linked hypophosphatemia. The study of TIO introduced the idea of the existence of circulating factors, referred to as 'phosphatonins', produced by the tumor, which act upon the kidney to reduce phosphate reabsorption. Although several factors have been identified, the phosphatonin FGF-23, also identified as the causative factor in ADHR, is currently the best characterized of these factors relative to phosphate handling. This review describes the importance of TIO in understanding phosphate homeostasis in the context of new endocrine interactions between the skeleton and the kidney.

Original languageEnglish (US)
Pages (from-to)435-442
Number of pages8
JournalExpert Review of Endocrinology and Metabolism
Issue number5
StatePublished - Sep 2009


  • FGF-23
  • Fibroblast growth factor-23
  • FRP4
  • Hypophosphatemia
  • MEPE
  • Oncogenic osteomalacia

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Tumor-induced osteomalacia'. Together they form a unique fingerprint.

Cite this